Black raspberries (BRB) are known to inhibit a wide range of cancers in the pre-clinical trials or models including the models of skin, oral, colon, breast, and esophageal cancer. Several promising preclinical results have led to the evaluations of clinical results in the patients who are at the higher risk of developing cancer.
Medical research that has investigated the role of black raspberries in offering the potential treatment for cancer in the coming times. The results of the studies in clinical settings of blackberries or raspberries (BRB) have revealed the positive effects of several cancers including preneoplastic lesions or colon, esophageal, and oral cancers. The treatment of cancers with black raspberries has resulted in the historical regression of oral intraepithelial neoplasia that is associated with the overall improvement in the histologic grade. In addition to this, the results have also revealed the significant reduction in the loss of heterozygosity at suppressing tumor with the modulated genes that are linked to the growth factor recycling & processing of the RNA in the colon.
Black raspberries (BRB) also results in the inhibition of the FAP-associated polyp progression along with suppressing the demethylated tumor genes and in improving the profiles of plasma cytokine. The consumption of Black raspberries (BRB) resulted in the increase in the overall tissue levels of GST-pi and decrease in the levels of 8-isoprostane. This serves to be a major marker of oxidative stress or lipid peroxidation.
As such, the consumption of black raspberries (BRB) can be observed with the prevention and treatment of cancer in the future times.